After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
DVAX belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Dynavax Technologies Corp is $1.21B. A total of 2.38 million shares were traded on the day, compared to an average of 1.67M shares.
In the most recent transaction, Myers Scott Dunseth bought 3,800 shares of DVAX for 10.82 per share on Aug 22 ’25. After the transaction, the Director now owns 35,004 company shares. In a previous transaction on Aug 21 ’25, Deep Track Biotechnology Maste sold 1,094,994 shares at 11.03 per share. DVAX shares that 10% Owner owns now total 16,696,492.
Among the insiders who sold shares, Deep Track Biotechnology Maste disposed of 970,143 shares on Aug 22 ’25 at a per-share price of $10.59. This resulted in the 10% Owner holding 15,726,349 shares of DVAX after the transaction. In another insider transaction, Novack David F sold 10,000 shares at $14.00 per share on Mar 24 ’25. Company shares held by the President & COO now total 8,078.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, DVAX has a high of $14.63 and a low of $9.20.
As of this writing, DVAX has an earnings estimate of $0.12 per share for the current quarter. EPS was calculated based on a consensus of 2.0 estimates, with a high estimate of $0.15 per share and a lower estimate of $0.09. The company reported an EPS of $0.12 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. DVAX’s latest balance sheet shows that the firm has $545.95M in Cash & Short Term Investments as of fiscal 2021. There were $257.38M in debt and $556.40M in liabilities at the time. Its Book Value Per Share was $4.22, while its Total Shareholder’s Equity was $222.37M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DVAX is Buy with a score of 3.80.
